A5047556989- Intraperitoneal and Appendiceal Malignancies
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Ovarian cancer diagnosis and treatment
- Neuroendocrine Tumor Research Advances
- Appendicitis Diagnosis and Management
- Gastric Cancer Management and Outcomes
- Management of metastatic bone disease
- Nanoparticle-Based Drug Delivery
- Adrenal and Paraganglionic Tumors
- Multiple and Secondary Primary Cancers
- Economic and Financial Impacts of Cancer
Radboud University Nijmegen
2022-2025
Maastricht University
2025
Catharina Ziekenhuis
2022-2025
Netherlands Comprehensive Cancer Organisation
2024-2025
Abstract This study aims to assess the influence of colorectal cancer screening on incidence synchronous peritoneal metastases (CPM). Patients diagnosed with CPM between 2009 and 2022 were selected from Netherlands Cancer Registry. Crude rates observed expected calculated per 100,000 individuals compared. Expected was extrapolated in years prior invitation. In total, 9,238 patients included. For screen‐eligible population (55–75 years), increased 5.1 (2009) 7.0 before initiation (2013)...
The objective of this study was to assess the incidence, treatment, and survival patients with synchronous peritoneal metastases (PM) from extraperitoneal primary tumors. A cohort selected Netherlands Cancer Registry (NCR), in which all diagnosed PM 2017 2018 were screened for eligibility. five most common origins included further analyses: lung, breast, urinary tract, kidney cancer malignant melanoma. Survival investigated using log-rank test between different tumor locations. In total, 480...
Peritoneal metastases (PMs) from colorectal cancer (CRC) respond poorly to treatment and are associated with unfavorable prognosis. For example, the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) cytoreductive surgery in resectable patients shows limited benefit, novel treatments urgently needed. The majority CRC-PMs represent CMS4 molecular subtype CRC, here we queried vulnerabilities this pharmacogenomic databases identify therapies. This reveals copper ionophore elesclomol...